Novel amino acid Schiff base Zn(II) complexes as new therapeutic approaches in diabetes and Alzheimer's disease: Synthesis, characterization, biological evaluation, and molecular docking studies

Basit Öğe Kaydı
dc.authoridaydin, ali/0000-0002-9550-9111
dc.authoridTaslimi, Parham/0000-0002-3171-0633
dc.authoridAkkus Tas, Nilay/0009-0004-8644-6659
dc.contributor.authorSenocak, Aysegul
dc.contributor.authorTas, Nilay A.
dc.contributor.authorTaslimi, Parham
dc.contributor.authorTuzun, Burak
dc.contributor.authorAydin, Ali
dc.contributor.authorKaradag, Ahmet
dc.date.accessioned2024-10-26T18:09:42Z
dc.date.available2024-10-26T18:09:42Z
dc.date.issued2022
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractSchiff bases are compounds that have gained importance in the paint industry due to their colorful nature and in the field of chemistry and biochemistry due to their biological activities. Various biological applications of Schiff bases, such as antitumor, antifungal, antibacterial, antioxidant, antituberculosis, and anthelmintic, have been widely studied. Within the scope of the study, 5-bromo-2-hydroxybenzaldehyde and amino acid methyl esters (isoleucine, phenylalanine, and methionine) and amino acid Schiff bases were synthesized first. The synthesis of the new Zn(II) complexes of these Schiff bases was carried out by the reaction of synthesized Schiff bases and Zn(OAc)(2)center dot 2H(2)O. The structures of the synthesized complexes were elucidated using elemental analysis, Fourier transform infrared, nuclear magnetic resonance, UV-visible, and thermal analysis spectroscopy techniques. These synthesized salts were found to be effective inhibitor compounds for the alpha-glycosidase, and acetylcholinesterase enzyme with Ki values in the range of 30.50 +/- 3.82-38.17 +/- 6.26 mu M for alpha-glycosidase, 3.68 +/- 0.54-10.27 +/- 1.68 mu M for butyrylcholinesterase, and 6.26 +/- 0.83-15.73 +/- 4.73 mu M for acetylcholinesterase, respectively.
dc.identifier.doi10.1002/jbt.22969
dc.identifier.issn1095-6670
dc.identifier.issn1099-0461
dc.identifier.issue3
dc.identifier.pmid34812557
dc.identifier.scopus2-s2.0-85119658246
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1002/jbt.22969
dc.identifier.urihttps://hdl.handle.net/20.500.12418/30239
dc.identifier.volume36
dc.identifier.wosWOS:000722258300001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofJournal of Biochemical and Molecular Toxicology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectamino acid Schiff base
dc.subjectenzyme inhibition
dc.subjectmolecular docking
dc.subjectZn(II) complexes
dc.titleNovel amino acid Schiff base Zn(II) complexes as new therapeutic approaches in diabetes and Alzheimer's disease: Synthesis, characterization, biological evaluation, and molecular docking studies
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu